Drug Profile
ZL 2302
Alternative Names: ZL2302Latest Information Update: 28 Jan 2020
Price :
$50
*
At a glance
- Originator Sanofi
- Developer ZAI Lab
- Class Antineoplastics
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer